Multispanning membrane protein SIDT2 increases knockdown activity of gapmer antisense oligonucleotides
Abstract Recent advances in the clinical development of oligonucleotide therapeutics, such as antisense oligonucleotides (ASOs) and small interfering RNAs, have attracted attention as promising therapeutic modalities for genetic and intractable diseases. These oligonucleotide therapeutics exert thei...
Saved in:
Main Authors: | Kohshi Kusumoto, Kiyomi Sasaki, Yasunori Uchida, Ayaka Utsumi, Tokuyuki Yoshida, Satoshi Obika, Takao Inoue, Keiichiro Okuhira |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-024-84310-6 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antisense oligonucleotides for the arterial hypertension mechanisms study and therapy
by: L. O. Klimov, et al.
Published: (2018-04-01) -
In vivo efficacy and safety of systemically administered serinol nucleic acid-modified antisense oligonucleotides in mouse kidney
by: Toshiki Tsuboi, et al.
Published: (2025-03-01) -
Personalized allele-specific antisense oligonucleotides for GNAO1-neurodevelopmental disorder
by: Inna Shomer, et al.
Published: (2025-03-01) -
Application of antisense oligonucleotide drugs in amyotrophic lateral sclerosis and Huntington’s disease
by: Kaili Ou, et al.
Published: (2025-01-01) -
Changes induced in mouse lipid metabolism by simultaneous impact of antisense oligonucleotide derivatives to <i>apoB</i>, <i>PCSK9</i>, and <i>apoCIII</i> mRNAs
by: S. I. Oshevski, et al.
Published: (2020-01-01)